medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 3

<< Back Next >>

Ann Hepatol 2012; 11 (3)

Acetylcholinesterase and butyrylcholinesterase as markers of low-grade systemic inflammation

Das UN

Language: English
References: 17
Page: 409-411
PDF size: 62.24 Kb.


Text Extraction

Dear Editor:
Low-grade systemic inflammation plays a significant role in the pathogenesis of insulin resistance, type 2 diabetes mellitus, hypertension, hyperlipidemias, Alzheimer’s disease, proliferative diabetic retinopathy; age-related macular degeneration, minimal change nephropathy and various rheumatological conditions.1,2 Hence, development of reliable, unique and robust markers is essential.


REFERENCES

  1. Das UN. Clinical laboratory tools to diagnose inflammation. Adv Clin Chemistry 2006; 41: 189-229.

  2. Das UN. Molecular Basis of Health and Disease. New York: Springer; 2011.

  3. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 2007; 12: RA214-RA221.

  4. Rao AA, Reddy CS, Sridhar GR, Annapurna A, Hanuman T, Prameela M, Suresh K, et al. Enhanced butyrylcholinesterase activity may be the common link in triggering lowgrade systemic inflammation and decrease in cognitive function in diabetes mellitus and Alzheimer’s disease. Current Nutr Food Sci 2008; 4: 213-16.

  5. Lampón N, Hermida-Cadahia EF, Riveiro A, Tutor JC. Association between butyrylcholinesterase activity and lowgrade systemic inflammation. Ann Hepatology 2012; 11(3): 356-63.

  6. Kaplay SS. Acetylcholinesterase and butyrylcholinesterase of developing human brain. Biol Neonate 1976; 28: 65-73.

  7. Jope RS, Walter-Ryan WG, Alarcon RD, Lally KM. Cholinergic processes in blood samples from patients with major psychiatric disorders. Biol Psychiatry 1985; 20: 1258-66.

  8. Taylor P. In: The Pharmacological Basis of Therapeutics. Hardman J, Limbird J, Molinoff P, Raddon R, Gilman A (eds.). New York: McGraw-Hill; 1996, p. 161-76.

  9. Godfrey DA, Matschinsky FM. Enzymes of the cholinergic system in islets of Langerhans. J Histochem Cytochem 1975; 23: 645-51.

  10. Abbott CA, Mackness MI, Kumar S, Olukoga AO, Gordon C, Arrol S, Bhatnagar D, et al. Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci (Lond) 1993; 85: 77-81.

  11. Alcantara VM, Chautard-Freire-Maia EA, Scartezini M, Cerci MS, Braun-Prado K, Picheth G. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest 2002; 62: 399-404.

  12. Mahmoud FF, Haines DD, Abdul HT, Omu AE, Abu-Donia MB. Butyrylcholinesterase activity in gestational diabetes: correlation with lymphocyte subpopulations in peripheral blood. Am J Reprod Immunol 2006; 56: 185-92.

  13. Calderon-Margalit R, Adler B, Abramson JH, Gofin J, Kark JD. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem 2006; 52: 845-52.

  14. Pavlov VA, Tracey KJ. Neural regulators of innate immune responses and inflammation. Cell Mol Life Sci 2004; 61: 2322-31.

  15. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-62.

  16. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, et al. Nicotinic acetylcholine receptor a7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-8.

  17. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.




2020     |     www.medigraphic.com